NYSE$EHAB

Enhabit Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Enhabit reported a slight decrease in total net service revenue but maintained adjusted EBITDA in the first quarter of 2024, driven by strong non-Medicare admissions in home health and cost management.

Enhabit, Inc. reported first-quarter 2024 financial results with total net service revenue of $262.4 million, a slight decrease from the previous year. Despite the revenue dip, the company maintained consolidated Adjusted EBITDA at $25.3 million, consistent with the prior year, primarily due to strong growth in home health Medicare Advantage admissions and effective cost control.

  • Net service revenue decreased by 1.0% year-over-year to $262.4 million.
  • Adjusted EBITDA remained flat at $25.3 million compared to the first quarter of 2023.
  • Home health non-Medicare admissions increased by 25.2%, driving total admission growth of 5.3% year-over-year.
  • General and administrative expenses declined year-over-year, contributing to sustained profitability.

Headline financials

Total Revenue

$262M

Previous: $265M-1.0%
EPS (adj)

$0.07

Previous: $0.05+40.0%
Adjusted EBITDA

$25.3M

No prior period
Adjusted EBITDA Margin

9.6%

No prior period
Home Health Admissions

56.8K

No prior period
Home Health Cost per Visit

$90.00

No prior period
Hospice Admissions

3.0K

No prior period
Hospice Patient Days

308.5K

No prior period
Hospice Average Daily Census

3.4K

No prior period
Hospice Revenue per Patient Day

$159.00

No prior period
Hospice Cost per Patient Day

$79.00

No prior period
Non-Medicare Admissions

30.9K

No prior period
Medicare Admissions

25.9K

No prior period
Total Home Health Visits

1.2M

No prior period
Capital Expenditures

-$1.8M

Previous: -$600K-200.0%
Net Income

$200K

Previous: $2.7M-92.6%
Operating Income

$12.9M

Previous: $14.2M-9.2%
Gross Profit

$128M

Previous: -$133M+196.7%

Revenue & EPS history

Enhabit · Revenue · Quarterly

$262M

Q1 2024-1%vs Q1 2023
Beat estimate in 3 of 4 quarters(75%)
ActualEstimate

Revenue by segment

Enhabit · $261M total across 2 segments · Q4 2024

  • Home Health
    $210M
  • Hospice
    $51.1M

Forward guidance

Enhabit reaffirmed its full-year 2024 guidance, projecting net service revenue between $1,076 million and $1,102 million, Adjusted EBITDA between $98 million and $110 million, and Adjusted EPS between $0.12 and $0.43.

Tailwinds

  • Continued focus on operational strategies to drive future growth.
  • Anticipated benefits from additional frontline clinicians.
  • Expectations of more and better home health payor contracts.
  • Continued control over general and administrative expenses.
  • Strategic initiatives aimed at increasing admissions in payor innovation contracts.

Headwinds

  • Potential impact of payor mix shift to more non-Medicare admissions on consolidated revenue.
  • Increased cost of service due to merit and market rate increases.
  • Uncertainty regarding the future impact of items outside the company's control on financial performance.
  • Potential for litigation, shareholder activism, and standalone transition costs.
  • Challenges in predicting the precise impact of market consolidation transactions on results of operations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+1.9%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+8.6%

Avg return

30 days after

40%

6 / 15 earnings

Positive

+18.2%

Q1 2025

Best reaction

-6.1%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%+0.1%
Q4 2025+0.0%+0.0%+2.9%
Q3 2025-6.1%-2.7%+13.6%
Q2 2025+15.2%+11.4%+15.1%
Q1 2025+18.2%+27.7%+31.7%
Q4 2024+1.6%+2.3%+13.3%
Q3 2024-0.4%-5.7%-12.0%
Q2 2024+0.0%-3.1%+14.8%
Q1 2024+0.0%-5.4%-13.4%
Q4 2022+0.0%-5.7%-0.4%
Q3 2023+6.1%+6.7%+19.3%
Q2 2023-2.6%-2.9%+5.6%
Q1 2023-4.5%-6.0%-2.0%
Q3 2022-0.1%+1.9%+11.3%
Q2 2022+1.7%+5.1%+20.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro